46,989 Shares in Biodesix, Inc. $BDSX Purchased by GSA Capital Partners LLP

Posted by Francis Steltz on Aug 18th, 2026

GSA Capital Partners LLP purchased a new stake in shares of Biodesix, Inc. (NASDAQ:BDSX – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 46,989 shares of the company’s stock, valued at approximately $1,060,000. GSA Capital Partners LLP owned about 0.45% of Biodesix as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. AIGH Capital Management LLC bought a new stake in shares of Biodesix during the 1st quarter worth approximately $10,996,000. XTX Topco Ltd grew its stake in shares of Biodesix by 99.4% in the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock valued at $58,000 after buying an additional 102,494 shares in the last quarter. Walleye Capital LLC acquired a new position in Biodesix during the second quarter worth $1,679,000. Stempoint Capital LP acquired a new position in Biodesix during the first quarter worth $1,015,000. Finally, Sei Investments Co. bought a new stake in Biodesix during the first quarter worth $624,000. Institutional investors and hedge funds own 20.96% of the company’s stock.

Wall Street Analyst Weigh In

BDSX has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $27.00 price objective (up from $26.00) on shares of Biodesix in a research report on Thursday, August 6th. Weiss Ratings raised shares of Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, June 12th. Roth Capital initiated coverage on shares of Biodesix in a research note on Wednesday, June 24th. They issued a “buy” rating and a $32.00 target price for the company. Finally, Canaccord Genuity Group lifted their price target on Biodesix from $27.00 to $35.00 and gave the stock a “buy” rating in a report on Monday, August 10th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $31.33.

Check Out Our Latest Research Report on Biodesix

Insider Transactions at Biodesix

In other news, Director Jack W. Schuler bought 15,000 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The shares were bought at an average price of $24.47 per share, with a total value of $367,050.00. Following the completion of the transaction, the director owned 555,810 shares of the company’s stock, valued at $13,600,670.70. This trade represents a 2.77% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have purchased 42,600 shares of company stock worth $1,033,062 in the last three months. Company insiders own 23.20% of the company’s stock.

Biodesix Trading Down 3.1%

BDSX stock opened at $23.25 on Tuesday. Biodesix, Inc. has a one year low of $5.26 and a one year high of $25.52. The stock has a market cap of $245.29 million, a price-to-earnings ratio of -7.33 and a beta of 0.56. The company has a fifty day moving average price of $20.67 and a two-hundred day moving average price of $16.32. The company has a debt-to-equity ratio of 5.12, a current ratio of 2.85 and a quick ratio of 2.85.

Biodesix (NASDAQ:BDSX – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.19. Biodesix had a negative net margin of 26.97% and a negative return on equity of 788.19%. The company had revenue of $26.86 million for the quarter, compared to analyst estimates of $26.03 million. Equities analysts anticipate that Biodesix, Inc. will post -2.68 EPS for the current year.

About Biodesix

(Free Report)

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.